These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7494223)

  • 41. Correspondence re: R. R. Love, The National Surgical Adjuvant Breast Project (NSABP) Breast Cancer Prevention Trial revisited. Cancer Epidemiol., Biomarkers & Prev., 2: 403-407, 1993.
    Williams GM; Hard GC
    Cancer Epidemiol Biomarkers Prev; 1994 Mar; 3(2):185-6. PubMed ID: 8049643
    [No Abstract]   [Full Text] [Related]  

  • 42. A clinical assessment of loading dose tamoxifen for advanced breast carcinoma.
    Ribeiro GG; Wilkinson PM
    Clin Oncol; 1984 Dec; 10(4):363-7. PubMed ID: 6509818
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tamoxifen: the long and short of it.
    Swain SM
    J Natl Cancer Inst; 1996 Nov; 88(21):1510-2. PubMed ID: 8901846
    [No Abstract]   [Full Text] [Related]  

  • 44. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
    Fallowfield LJ; Bliss JM; Porter LS; Price MH; Snowdon CF; Jones SE; Coombes RC; Hall E
    J Clin Oncol; 2006 Feb; 24(6):910-7. PubMed ID: 16484701
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The breast cancer prevention trial: should women at risk take tamoxifen?
    McKeon VA
    J Obstet Gynecol Neonatal Nurs; 1999; 28(6 Suppl 1):34-8. PubMed ID: 10608495
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tamoxifen therapy for patients with breast cancer.
    Litton J; Buzdar A; Mac Gregor MC; Gonzalez-Angulo A; Hortobagyi G
    Lancet; 2013 Jun; 381(9883):2077-8. PubMed ID: 23769223
    [No Abstract]   [Full Text] [Related]  

  • 49. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01.
    Sacco M; Valentini M; Belfiglio M; Pellegrini F; De Berardis G; Franciosi M; Nicolucci A;
    J Clin Oncol; 2003 Jun; 21(12):2276-81. PubMed ID: 12805326
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group.
    Delozier T; Spielmann M; Macé-Lesec'h J; Janvier M; Hill C; Asselain B; Julien JP; Weber B; Mauriac L; Petit JC; Kerbrat P; Malhaire JP; Vennin P; Leduc B; Namer M
    J Clin Oncol; 2000 Oct; 18(20):3507-12. PubMed ID: 11032592
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation.
    Lancet; 1985 Apr; 1(8433):836-40. PubMed ID: 2858709
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
    Cella D; Fallowfield L; Barker P; Cuzick J; Locker G; Howell A;
    Breast Cancer Res Treat; 2006 Dec; 100(3):273-84. PubMed ID: 16944295
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [For how long should breast cancer patients take Tamoxifen? The International Program ATLAS will answer this question].
    Semiglazov VF
    Vopr Onkol; 1998; 44(4):373-7. PubMed ID: 9807196
    [No Abstract]   [Full Text] [Related]  

  • 54. Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial.
    Chiesa MD; Passalacqua R; Michiara M; Franciosi V; Di Costanzo F; Bisagni G; Camisa R; Buti S; Tomasello G; Cocconi G;
    Acta Biomed; 2007 Dec; 78(3):204-9. PubMed ID: 18330080
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Breast cancer--tamoxifen and tamoxifen analogues for the treatment of breast cancer].
    Iino Y; Morishita Y
    Nihon Rinsho; 1994 Mar; 52(3):797-803. PubMed ID: 8164385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
    Mamounas EP; Bryant J; Lembersky B; Fehrenbacher L; Sedlacek SM; Fisher B; Wickerham DL; Yothers G; Soran A; Wolmark N
    J Clin Oncol; 2005 Jun; 23(16):3686-96. PubMed ID: 15897552
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intestinal and pelvic endometriosis presenting as a tumor and associated with tamoxifen therapy: report of a case.
    Hajjar LR; Kim W; Nolan GH; Turner S; Raju UR
    Obstet Gynecol; 1993 Oct; 82(4 Pt 2 Suppl):642-4. PubMed ID: 8377997
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer.
    Alonso-Muñoz MC; Ojeda-González MB; Beltran-Fabregat M; Dorca-Ribugent J; López-López L; Borrás-Balada J; Cardenal-Alemany F; Gómez-Batiste X; Fabregat-Mayol J; Viladiu-Quemada P
    Oncology; 1988; 45(5):350-3. PubMed ID: 3045726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.